@inbook{be1f3b727e1a404dadcd17defd53baf3,
title = "Microbiome and Cardiovascular Disease",
abstract = "Atherosclerotic cardiovascular disease (ASCVD) is a prime example of a systems disease. In the initial phase, apolipoprotein B-containing cholesterol-rich lipoproteins deposit excess cholesterol in macrophage-like cells that subsequently develop into foam cells. A multitude of systemic as well as environmental factors are involved in further progression of atherosclerotic plaque formation. In recent years, both oral and gut microbiota have been proposed to play an important role in the process at different stages. Particularly bacteria from the oral cavity may easily reach the circulation and cause low-grade inflammation, a recognized risk factor for ASCVD. Gut-derived microbiota on the other hand can influence host metabolism on various levels. Next to translocation across the intestinal wall, these prokaryotes produce a great number of specific metabolites such as trimethylamine and short-chain fatty acids but can also metabolize endogenously formed bile acids and convert these into metabolites that may influence signal transduction pathways. In this overview, we critically discuss the novel developments in this rapidly emerging research field.",
keywords = "ASCVD, Atherosclerosis, Bacteriophage, Bile acids, SCFA, TMAO",
author = "Hilde Herrema and Max Nieuwdorp and Groen, {Albert K.}",
note = "Funding Information: MN is supported by a ZONMW-VIDI grant 2013 [016.146.327] and a Dutch Heart Foundation CVON IN CONTROL Young Talent Grant 2013. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
doi = "https://doi.org/10.1007/164_2020_356",
language = "English",
volume = "270",
series = "Handbook of Experimental Pharmacology",
publisher = "Springer Science and Business Media Deutschland GmbH",
pages = "311--334",
booktitle = "Handbook of Experimental Pharmacology",
address = "Germany",
}